Posology : מינונים

4.2   Posology and method of administration
Posology
Cardioxane is administered by a short intravenous infusion (15 minutes), approximately 30 minutes prior to anthracycline administration at a dose equal to 10 times the doxorubicin-equivalent dose and 10 times the epirubicin-equivalent dose.

Thus it is recommended that Cardioxane is given at a dose of 500 mg/m2 when the commonly used dosage schedule for doxorubicin of 50 mg/m2 is employed or 600 mg/m2 when the commonly used dosage schedule for epirubicin of 60 mg/m2 is employed.

Paediatric population
Cardioxane is not indicated for children and adolescents under 18 years old.
The safety and efficacy of Cardioxane in children aged 0 to 18 years have not been established.

Renal impairment
In patients with moderate to severe renal impairment (creatinine clearance < 40 ml/min) the dexrazoxane dose should be reduced by 50% (see section 4.4).

Hepatic impairment
The dosage ratio should be kept, i.e. if the anthracycline dose is reduced the dexrazoxane dose should be reduced accordingly.

Method of administration
Intravenous use

For instructions on reconstitution and dilution of the medicinal product before administration, see section 6.6.